Opinion|Videos|October 16, 2024
Patient Education and Emerging Therapies
Key Takeaways
- Clear communication and personalized care plans enhance patient understanding and adherence to treatment for type 2 inflammatory conditions.
- Utilizing tailored educational resources ensures patients comprehend their condition and the importance of adhering to treatment plans.
Panelists discuss how health care providers can improve patient education and support for type 2 inflammatory conditions through personalized communication strategies and shared decision-making, while also evaluating the role of emerging biologic therapies in treatment plans based on individual patient factors, disease severity, and biomarker profiles.
Advertisement
Episodes in this series
- How can health care providers better educate and support patients in understanding type 2 inflammatory conditions and adhering to treatment plans?
- What are your perspectives on the emerging biologic therapies targeting type 2 inflammation? How do you determine when these treatments may be appropriate for your patients?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
3
Disability, Economic Toll of Multimorbidity Climb in Older Adults
4
October FDA Approvals Bring Advances Across 5 Specialties
5